Business
Completion of Transaction
Completion of Transaction.
About this update from Niox Group Plc
[{"type":"text","content":"\n \n \n RNS Number : 1433O\n Circassia Group Plc\n 28 May 2020\n \n \n \n \n 28 May 2020\n \n \n Circassia Group plc\n \n \n Completion of Transaction\n \n \n Circassia Group plc (\"Circassia\" or \"the Company\") announces that the proposed transfer of the Tudorza and Duaklir assets to AstraZeneca first announced on 9 April 2020 has now completed.\n \n \n \n \n \n Ian Johnson, Executive Chairman of Circassia, said: \"The completion of this transaction transforms Circassia into a debt-free business. Niox® is a highly differentiated respiratory diagnostic platform that will be able to deliver long-term growth and enhanced shareholder returns.\"\n \n \n \n -Ends-\n \n \n For further information, please contact:\n \n \n \n \n \n Circassia Group plc\n \n \n \n \n \n Ian Johnson, Executive Chairman\n \n \n \n \n \n \n \n \n \n \n c/o Peel Hunt\n \n \n \n \n \n \n Michael Roller, CFO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Peel Hunt (Nominated Adviser and Joint Broker)\n \n \n \n \n Tel: +44 (0) 20 7418 8900\n \n \n \n \n \n \n James Steel / Oliver Jackson\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap (Joint Broker)\n \n \n \n \n Tel: +44 (0) 20 7220 0500\n \n \n \n \n \n \n Geoff Nash / Alice Lane\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Numis Securities (Joint Broker)\n \n \n \n \n Tel: +44 (0) 20 7260 1000\n \n \n \n \n \n \n James Black / Duncan Monteith\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.\n END\n \n DISFFFEIEVIDFII\n ","length":6977,"tagName":"div"}]